Relationship between nonalcoholic fatty liver disease and liver fibrosis risk scales and various cardiometabolic risk scales in 219.477 Spanish workers
[eng] Introduction: Non-alcoholic fatty liver disease (NAFLD) is the main cause of chronic liver disease in the West, and in late stages it can lead to cirrhosis, which is expected to become the most frequent indication for liver transplantation in the next decade. Material and met...
| Autores: | , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universidad de las Islas Baleares |
| Repositorio: | Biblioteca Digital de les Illes Balears |
| OAI Identifier: | medicinaBalear:AJHS_Medicina_Balear_2023v38n5p138 |
| Acceso en línea: | http://ibdigital.uib.es/greenstone/sites/oai-site/collect/medicinaBalear/index/assoc/AJHS_Med/icina_Ba/lear_202/3v38n5p1/38.dir/AJHS_Medicina_Balear_2023v38n5p138.pdf http://ibdigital.uib.es/greenstone/library/collection/medicinaBalear/document/AJHS_Medicina_Balear_2023v38n5p138 |
| Access Level: | acceso abierto |
| Palabra clave: | Liver -- Diseases Health Sciences |
| Sumario: | [eng] Introduction: Non-alcoholic fatty liver disease (NAFLD) is the main cause of chronic liver disease in the West, and in late stages it can lead to cirrhosis, which is expected to become the most frequent indication for liver transplantation in the next decade. Material and methods: Descriptive and cross-sectional study in 219.477 Spanish workers in which the risk of presenting NASH and liver fibrosis was determined with 7 different scales and the cardiometabolic risk established from atherogenic indices, metabolic syndrome, atherogenic dyslipidemia, lipid triad and risk of prediabetes applying the PRISQ scale. Results: There was an increase in the mean values and in the prevalence of high-risk values of all the NASH and liver fibrosis scales in persons at high cardiometabolic risk compared to those at lower risk. Conclusions: There is a good relationship between the NASH and liver fibrosis risk scales and the cardiometabolic risk scales analyzed. |
|---|